Most big commercial health plans rarely prefer biosimilars

Ten of the 17 largest commercial health plans in the U.S. chose not to offer preferred coverage for less-expensive biosimilar drugs last year, according to an analysis cited by STAT.

The study, published May 19 in JAMA, found that the country's largest commercial health plans rarely offer preferred coverage to biosimilars, which are drugs that are nearly identical versions of biologic drugs but are less expensive.